The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.
A new AAN position statement outlines guidelines for switching from branded biologics to biosimilars, while preserving clinical autonomy for physicians.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results